We are live on ! Find out more
KLRS

Kalaris Therapeutics
KLRS

84 hedge funds and large institutions have $329M invested in Kalaris Therapeutics in 2021 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 25 increasing their positions, 27 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

102% more call options, than puts

Call options by funds: $647K | Put options by funds: $321K

50% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 12

6% more funds holding

Funds holding: 79 → 84 (+5)

0.01% less ownership

Funds ownership: 1.71% → 1.7% (-0.01%)

7% less repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 27

49% less capital invested

Capital invested by funds: $640M → $329M (-$311M)

Holders
84
Holders Change
+5
Holders Change %
+6.33%
% of All Funds
1.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
25
Reduced
27
Closed
12
Calls
$647K
Puts
$321K
Net Calls
+$326K
Net Calls Change
-$1M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$7.16M
2
Marshall Wace
Marshall Wace
United Kingdom
+$6.61M
3
GC
GMT Capital
Georgia
+$3.94M
4
GCP
GSA Capital Partners
United Kingdom
+$2.21M
5
Bank of America
Bank of America
North Carolina
+$1.94M

Top Sellers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
-$7.51M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$6.72M
3
Alkeon Capital Management
Alkeon Capital Management
New York
-$6.61M
4
ACH
ArrowMark Colorado Holdings
Colorado
-$3.13M
5
JP Morgan Chase
JP Morgan Chase
New York
-$3.01M
Name Holding Trade Value Shares
Change 		Change in
Stake
Lido Advisors
26
Lido Advisors
California
$1.03M – – –
Swiss National Bank
27
Swiss National Bank
Switzerland
$1.02M – – –
AA
28
ALPS Advisors
Colorado
$975K -$89.1K -192 -6%
Millennium Management
29
Millennium Management
New York
$901K +$1.4M +3,026 New
UBS Group
30
UBS Group
Switzerland
$827K +$400K +863 +45%
Rafferty Asset Management
31
Rafferty Asset Management
New York
$816K +$483K +1,042 +61%
Citadel Advisors
32
Citadel Advisors
Florida
$778K +$1.21M +2,614 New
Citigroup
33
Citigroup
New York
$743K +$510K +1,100 +79%
Dimensional Fund Advisors
34
Dimensional Fund Advisors
Texas
$635K +$990K +2,133 New
Morgan Stanley
35
Morgan Stanley
New York
$632K -$111K -239 -10%
California State Teachers Retirement System (CalSTRS)
36
California State Teachers Retirement System (CalSTRS)
California
$599K +$19.9K +43 +2%
TI
37
Trexquant Investment
Connecticut
$461K +$718K +1,548 New
UBS AM
38
UBS AM
Illinois
$393K +$65.9K +142 +12%
RhumbLine Advisers
39
RhumbLine Advisers
Massachusetts
$358K -$10.2K -22 -2%
Susquehanna International Group
40
Susquehanna International Group
Pennsylvania
$356K +$146K +314 +36%
Deutsche Bank
41
Deutsche Bank
Germany
$342K -$31.1K -67 -6%
State of Wisconsin Investment Board
42
State of Wisconsin Investment Board
Wisconsin
$327K – – –
FFN
43
Focus Financial Network
Minnesota
$325K – – –
Tudor Investment Corp
44
Tudor Investment Corp
Connecticut
$319K +$498K +1,073 New
Osaic Holdings
45
Osaic Holdings
Arizona
$306K -$26K -56 -5%
SFI
46
Susquehanna Fundamental Investments
Pennsylvania
$295K -$20.4K -44 -4%
CS
47
Credit Suisse
Switzerland
$293K -$77.9K -168 -15%
AllianceBernstein
48
AllianceBernstein
Tennessee
$289K -$688K -1,484 -60%
CSS
49
Cubist Systematic Strategies
Connecticut
$276K +$76.5K +165 +22%
New York State Common Retirement Fund
50
New York State Common Retirement Fund
New York
$275K -$928 -2 -0.2%
1
2
3 4

KLRS Hedge Fund Activity: Q4 2021 in Review

84 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q4 2021, worth a combined $329M — down 49% from $640M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new KLRS positions and 12 closed out — a net gain of 6 holders — while 25 added to existing stakes and 27 trimmed.

The largest buyer was BlackRock, adding an estimated $7.16M. The largest seller was Woodline Partners, cutting an estimated $7.51M.

  • 84 institutional investors held Kalaris Therapeutics (KLRS) as of Q4 2021, up from 79 in Q3 2021.
  • Funds reported $329M of Kalaris Therapeutics stock for Q4 2021, down 49% quarter-over-quarter.
  • 18 funds opened new Kalaris Therapeutics positions in Q4 2021 and 12 closed out, a net change of +6 holders.
  • The largest Kalaris Therapeutics buyer in Q4 2021 was BlackRock, an estimated $7.16M added.
  • The largest Kalaris Therapeutics seller in Q4 2021 was Woodline Partners, an estimated $7.51M sold.

Based on aggregated 13F filings for Q4 2021.